These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26670048)

  • 1. Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization.
    Del Pozo Martin Y; Park D; Ramachandran A; Ombrato L; Calvo F; Chakravarty P; Spencer-Dene B; Derzsi S; Hill CS; Sahai E; Malanchi I
    Cell Rep; 2015 Dec; 13(11):2456-2469. PubMed ID: 26670048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
    Konen JM; Rodriguez BL; Padhye A; Ochieng JK; Gibson L; Diao L; Fowlkes NW; Fradette JJ; Peng DH; Cardnell RJ; Kovacs JJ; Wang J; Byers LA; Gibbons DL
    Cancer Res; 2021 Mar; 81(5):1398-1412. PubMed ID: 33402388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.
    Goyette MA; Duhamel S; Aubert L; Pelletier A; Savage P; Thibault MP; Johnson RM; Carmeliet P; Basik M; Gaboury L; Muller WJ; Park M; Roux PP; Gratton JP; Côté JF
    Cell Rep; 2018 May; 23(5):1476-1490. PubMed ID: 29719259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long noncoding RNA H19 regulates HIF-1α/AXL signaling through inhibiting miR-20b-5p in endometrial cancer.
    Zhu H; Jin YM; Lyu XM; Fan LM; Wu F
    Cell Cycle; 2019 Oct; 18(19):2454-2464. PubMed ID: 31411527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
    Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
    Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
    Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
    Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.
    Ciardiello D; Blauensteiner B; Matrone N; Belli V; Mohr T; Vitiello PP; Martini G; Poliero L; Cardone C; Napolitano S; De Falco V; Giunta EF; Ciaramella V; Corte CD; Barra G; Selvaggi F; Franco R; Marino FZ; Cuomo A; Morgillo F; Troiani T; Sibilia M; Ciardiello F; Martinelli E
    Med Oncol; 2021 Feb; 38(3):24. PubMed ID: 33570712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGFβ promotes YAP-dependent AXL induction in mesenchymal-type lung cancer cells.
    Choi JY; Lee H; Kwon EJ; Kong HJ; Kwon OS; Cha HJ
    Mol Oncol; 2021 Feb; 15(2):679-696. PubMed ID: 33207077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.
    D'Assoro AB; Liu T; Quatraro C; Amato A; Opyrchal M; Leontovich A; Ikeda Y; Ohmine S; Lingle W; Suman V; Ecsedy J; Iankov I; Di Leonardo A; Ayers-Inglers J; Degnim A; Billadeau D; McCubrey J; Ingle J; Salisbury JL; Galanis E
    Oncogene; 2014 Jan; 33(5):599-610. PubMed ID: 23334326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NANOG signaling promotes metastatic capability of immunoedited tumor cells.
    Lee HJ; Noh KH; Lee YH; Song KH; Oh SJ; Kim SY; Kim TW
    Clin Exp Metastasis; 2015 Jun; 32(5):429-39. PubMed ID: 25899063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
    Wu F; Li J; Jang C; Wang J; Xiong J
    Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells.
    Asiedu MK; Beauchamp-Perez FD; Ingle JN; Behrens MD; Radisky DC; Knutson KL
    Oncogene; 2014 Mar; 33(10):1316-24. PubMed ID: 23474758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
    Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
    Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.
    Du W; Sun L; Liu T; Zhu J; Zeng Y; Zhang Y; Wang X; Liu Z; Huang JA
    Oncol Rep; 2020 Jul; 44(1):185-195. PubMed ID: 32319651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
    Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG
    Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
    Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y
    Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
    Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
    Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
    Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
    Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells.
    Cheng P; Phillips E; Kim SH; Taylor D; Hielscher T; Puccio L; Hjelmeland AB; Lichter P; Nakano I; Goidts V
    Stem Cell Reports; 2015 May; 4(5):899-913. PubMed ID: 25921812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six1 promotes epithelial-mesenchymal transition and malignant conversion in human papillomavirus type 16-immortalized human keratinocytes.
    Xu H; Zhang Y; Altomare D; Peña MM; Wan F; Pirisi L; Creek KE
    Carcinogenesis; 2014 Jun; 35(6):1379-88. PubMed ID: 24574515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.